Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07325292 · ClinicalTrials.gov registry record · Phase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
A Phase 3 study of Multiple Sclerosis, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 10
- Study locations
NCT07325292: Recruiting Phase 3 study of Multiple Sclerosis, sponsored by Sanofi.
NCT07325292 is a Phase 3 study of Multiple Sclerosis that is actively recruiting participants, run by Sanofi. The registered enrollment target is 160 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (73% lower). The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07325292, a Phase 3 study of Multiple Sclerosis, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a randomized, open-label, parallel, Phase 3 study with 2-arms for treatment. The purpose of this study is to evaluate SC administration of frexalimab every 4 weeks (q4w) compared to IV administration of frexalimab q4w in male and female participants with RMS and nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with MS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: The study intervention duration will be 48 weeks (12 months) for Parts A and B combined. Optional Part C will last until the initiation of a long term safety study for Frexalimab.The follow up duration after the end of study intervention (in case of discontinuation) will be 6 months. The number of scheduled visits (Parts A and B) will be 17 or 11 for participants receiving frexalimab SC or IV, respectively, with an on-site visit frequency of every month between Week 4 and Week 24 in Part A, then every 1 to 3 months in Part B, then every 6 months in Part C. Participants discontinuing treatment before the End of Study will have an additional 3 follow-up visits.
Primary Outcome
AUCW20-W24
Conditions Studied
Interventions
- DRUG Frexalimab
- DRUG MRI contrast-enhancing preparations
Study Locations (10)
Florida
- Neurology of Central Florida- Site Number : 8400147 - Altamonte Springs
- Aqualane Clinical Research- Site Number : 8400026 - Naples
- Neurology Associates of Ormond Beach- Site Number : 8400086 - Ormond Beach
Alabama
- North Central Neurology Associates- Site Number : 8401100 - Cullman
- Alabama Neurology Associates- Site Number : 8400115 - Homewood
North Carolina
- Piedmont HealthCare - Lake Norman Neurology- Site Number : 8400002 - Charlotte
- Raleigh Neurology Associates- Site Number : 8400014 - Raleigh
Arizona
- Perseverance Research Center- Site Number : 8400138 - Scottsdale
California
- Private Practice - Dr. Regina Berkovich- Site Number : 8400005 - West Hollywood
Tennessee
- Hope Neurology- Site Number : 8400019 - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-01-14 |
| Est. Completion | 2028-11-30 |
| Phase | Phase 3 |
What NCT07325292 shows while recruiting
NCT07325292 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Frexalimab is the first listed.
NCT07325292 lists 10 locations in 6 states (Florida, Alabama, North Carolina).
Frequently Asked Questions
What is clinical trial NCT07325292 about?
NCT07325292 is a clinical study titled "Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis". This is a randomized, open-label, parallel, Phase 3 study with 2-arms for treatment. The purpose of this study is to evaluate SC administration of frexalimab every 4 weeks (q4w) compared to IV administration of frexalimab q4w in male and female participants with RMS and nrSPMS (aged 18 to 60 years ...
What is the current status of trial NCT07325292?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2026-01-14. Estimated completion is 2028-11-30.
What conditions does trial NCT07325292 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT07325292?
The interventions under investigation include: Frexalimab (DRUG), MRI contrast-enhancing preparations (DRUG).
Who is sponsoring clinical trial NCT07325292?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07325292 being conducted?
This trial has 10 study locations across Alabama, Arizona, California, Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07325292's enrollment target sits among peer trials
160 89th of 315 higher than 226 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 3
-
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI